Literature DB >> 23415926

The management of overactive bladder refractory to medical therapy.

Dudley Robinson1, Ilias Giarenis, Linda Cardozo.   

Abstract

Overactive bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence and is usually associated with frequency and nocturia. Whilst many women may be initially managed using a clinical diagnosis alone a number will fail primary therapy and will require further investigation. Those women with refractory symptoms following initial conservative and medical therapy may benefit from alternative treatment modalities including intravesical Botulinum toxin, neuromodulation or reconstructive surgery. This review, the second of two covering the treatment of intractable OAB symptoms in women, will focus on management following the failure of medical therapy. It will principally focus on the role of Botulinum toxin, neuromodulation and reconstructive surgery.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23415926     DOI: 10.1016/j.maturitas.2013.01.013

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

Review 1.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

2.  Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents.

Authors:  Abbigail Woll; Autumn Edenfield; Mallory Locke; Steven Swift
Journal:  Int Urogynecol J       Date:  2021-02-23       Impact factor: 2.894

3.  Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery.

Authors:  Pawel Miotla; Konrad Futyma; Rufus Cartwright; Michal Bogusiewicz; Katarzyna Skorupska; Ewa Markut-Miotla; Tomasz Rechberger
Journal:  Int Urogynecol J       Date:  2015-09-12       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.